Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study
Hieu Trong Nguyen,1 Kien Hung Do,2 Nguyen Ba Le,3 Thang Tran4 1Department of Medical Oncology 2, Hanoi Oncology Hospital, Hanoi, Vietnam; 2Department of Medical Oncology 1, National Cancer Hospital of Vietnam, Hanoi, Vietnam; 3Ha Thanh Hospital, Hanoi, Vietnam; 4Department of Medical Oncology 4, Nat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-09-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/treatment-outcome-and-safety-of-the-tcx-regimen-for-advanced-gastric-c-peer-reviewed-fulltext-article-CMAR |
| _version_ | 1811272389984518144 |
|---|---|
| author | Nguyen HT Do KH Le NB Tran T |
| author_facet | Nguyen HT Do KH Le NB Tran T |
| author_sort | Nguyen HT |
| collection | DOAJ |
| description | Hieu Trong Nguyen,1 Kien Hung Do,2 Nguyen Ba Le,3 Thang Tran4 1Department of Medical Oncology 2, Hanoi Oncology Hospital, Hanoi, Vietnam; 2Department of Medical Oncology 1, National Cancer Hospital of Vietnam, Hanoi, Vietnam; 3Ha Thanh Hospital, Hanoi, Vietnam; 4Department of Medical Oncology 4, National Cancer Hospital of Vietnam, Hanoi, VietnamCorrespondence: Hieu Trong Nguyen, Department of Medical Oncology 2, Hanoi Oncology Hospital, 42A Thanh Nhan, Thanh Nhan, Hai Ba Trung, Hanoi, Vietnam, Tel +84 983230112, Email hieunt@bvubhn.vnObjective: To evaluate the outcome and safety of the paclitaxel, carboplatin, and capecitabine (TCX) regimen in patients with advanced gastric cancer.Methods: Advanced gastric cancer patients received the TCX regimen for up to six cycles, which were 3 weeks apart. Paclitaxel (175 mg/m2) was given over a 3-hour infusion, followed by carboplatin in a 1-hour infusion on day 1. Capecitabine (850 mg/m2) was given orally twice daily from day 1 to day 14. Primary endpoints were progression-free survival (PFS) and overall survival (OS).Results: Among 83 patients at stage IVa and IVb, the median PFS was 9.3 months; 6-month, 1-year, and 2-year PFS were 74.6%, 32.5%, and 14.4%, respectively. The median OS was 17.0 months; 6-month, 1-year, and 2-year OS were 97.5%, 68.7%, and 21.7%, respectively. In the multivariable Cox regression model, higher CEA was associated with poor OS. Common adverse events included hand-food syndrome (77.9%), peripheral neuropathy (63.2%), fatigue (68.7%), and nausea (54.2%).Conclusion: The TCX regimen provided good survival and a better safety profile. More clinical trials are needed to confirm its treatment efficacy and safety, especially in comparison with other triplet regimens.Keywords: paclitaxel, carboplatin, capecitabine, advanced gastric cancer, efficacy |
| first_indexed | 2024-04-12T22:39:27Z |
| format | Article |
| id | doaj.art-8053a4d557c84e909df8baf823426755 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-04-12T22:39:27Z |
| publishDate | 2022-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-8053a4d557c84e909df8baf8234267552022-12-22T03:13:47ZengDove Medical PressCancer Management and Research1179-13222022-09-01Volume 142825283778363Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort StudyNguyen HTDo KHLe NBTran THieu Trong Nguyen,1 Kien Hung Do,2 Nguyen Ba Le,3 Thang Tran4 1Department of Medical Oncology 2, Hanoi Oncology Hospital, Hanoi, Vietnam; 2Department of Medical Oncology 1, National Cancer Hospital of Vietnam, Hanoi, Vietnam; 3Ha Thanh Hospital, Hanoi, Vietnam; 4Department of Medical Oncology 4, National Cancer Hospital of Vietnam, Hanoi, VietnamCorrespondence: Hieu Trong Nguyen, Department of Medical Oncology 2, Hanoi Oncology Hospital, 42A Thanh Nhan, Thanh Nhan, Hai Ba Trung, Hanoi, Vietnam, Tel +84 983230112, Email hieunt@bvubhn.vnObjective: To evaluate the outcome and safety of the paclitaxel, carboplatin, and capecitabine (TCX) regimen in patients with advanced gastric cancer.Methods: Advanced gastric cancer patients received the TCX regimen for up to six cycles, which were 3 weeks apart. Paclitaxel (175 mg/m2) was given over a 3-hour infusion, followed by carboplatin in a 1-hour infusion on day 1. Capecitabine (850 mg/m2) was given orally twice daily from day 1 to day 14. Primary endpoints were progression-free survival (PFS) and overall survival (OS).Results: Among 83 patients at stage IVa and IVb, the median PFS was 9.3 months; 6-month, 1-year, and 2-year PFS were 74.6%, 32.5%, and 14.4%, respectively. The median OS was 17.0 months; 6-month, 1-year, and 2-year OS were 97.5%, 68.7%, and 21.7%, respectively. In the multivariable Cox regression model, higher CEA was associated with poor OS. Common adverse events included hand-food syndrome (77.9%), peripheral neuropathy (63.2%), fatigue (68.7%), and nausea (54.2%).Conclusion: The TCX regimen provided good survival and a better safety profile. More clinical trials are needed to confirm its treatment efficacy and safety, especially in comparison with other triplet regimens.Keywords: paclitaxel, carboplatin, capecitabine, advanced gastric cancer, efficacyhttps://www.dovepress.com/treatment-outcome-and-safety-of-the-tcx-regimen-for-advanced-gastric-c-peer-reviewed-fulltext-article-CMARpaclitaxelcarboplatincapecitabineadvanced gastric cancerefficacy |
| spellingShingle | Nguyen HT Do KH Le NB Tran T Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study Cancer Management and Research paclitaxel carboplatin capecitabine advanced gastric cancer efficacy |
| title | Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study |
| title_full | Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study |
| title_fullStr | Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study |
| title_full_unstemmed | Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study |
| title_short | Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study |
| title_sort | treatment outcome and safety of the tcx regimen for advanced gastric cancer a prospective cohort study |
| topic | paclitaxel carboplatin capecitabine advanced gastric cancer efficacy |
| url | https://www.dovepress.com/treatment-outcome-and-safety-of-the-tcx-regimen-for-advanced-gastric-c-peer-reviewed-fulltext-article-CMAR |
| work_keys_str_mv | AT nguyenht treatmentoutcomeandsafetyofthetcxregimenforadvancedgastriccanceraprospectivecohortstudy AT dokh treatmentoutcomeandsafetyofthetcxregimenforadvancedgastriccanceraprospectivecohortstudy AT lenb treatmentoutcomeandsafetyofthetcxregimenforadvancedgastriccanceraprospectivecohortstudy AT trant treatmentoutcomeandsafetyofthetcxregimenforadvancedgastriccanceraprospectivecohortstudy |